Bicycle Therapeutics today announced the appointment of Andy Sandham as non-executive Chairman. Andy brings over 30 years experience in building biotechnology businesses. He will work closely with founders, Sir Gregory Winter, FRS and Christian Heinis, and CEO, Dr John Tite, to drive the discovery and development of a new generation of biotherapeutics using the company’s proprietary bicyclic peptide technology. In addition to Andy’s appointment, Bruce Booth will be joining the Board to replace Regina Hodits as the Atlas Venture representative director.
Andy Sandham
Andy Sandham has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP. Andy is currently also Chairman and CEO of Kymab and is a non-executive director of NeurAxon and PBL.
“We are delighted to welcome Andy as our chairman. Andy has a wealth of experience in the biotechnology arena that will be invaluable as we look to continue to build our business. I would also like to thank Regina Hodits for the major contribution that she has made to the initial development of the company and we look forward to working with Bruce on the Board of Directors, ’’ said John Tite.
Andy Sandham said, “Bicycle has an extraordinary technology platform that has the potential to combine the proven benefits of therapeutic antibodies with the attractive features and manufacturing simplicity of small molecules. I am very excited to be working with Greg Winter, John Tite and the board as we enter the drug discovery and pharma partnering stage of our corporate development.”
